- Home
- PW vs ONCT Comparison
PW vs ONCT Comparison
Compare PW & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PW
- ONCT
- Stock Information
- Founded
- PW 1967
- ONCT N/A
- Country
- PW United States
- ONCT United States
- Employees
- PW N/A
- ONCT N/A
- Industry
- PW Real Estate Investment Trusts
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- PW Real Estate
- ONCT Health Care
- Exchange
- PW Nasdaq
- ONCT Nasdaq
- Market Cap
- PW 4.9M
- ONCT 4.3M
- IPO Year
- PW N/A
- ONCT N/A
- Fundamental
- Price
- PW $1.06
- ONCT $1.13
- Analyst Decision
- PW
- ONCT Buy
- Analyst Count
- PW 0
- ONCT 3
- Target Price
- PW N/A
- ONCT $10.00
- AVG Volume (30 Days)
- PW 64.3K
- ONCT 157.5K
- Earning Date
- PW 10-31-2024
- ONCT 11-06-2024
- Dividend Yield
- PW N/A
- ONCT N/A
- EPS Growth
- PW N/A
- ONCT N/A
- EPS
- PW N/A
- ONCT N/A
- Revenue
- PW $3,153,209.00
- ONCT $2,161,000.00
- Revenue This Year
- PW N/A
- ONCT $113.76
- Revenue Next Year
- PW N/A
- ONCT N/A
- P/E Ratio
- PW N/A
- ONCT N/A
- Revenue Growth
- PW N/A
- ONCT 227.92
- 52 Week Low
- PW $0.40
- ONCT $1.03
- 52 Week High
- PW $2.75
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- PW 45.07
- ONCT 37.09
- Support Level
- PW $1.00
- ONCT $1.03
- Resistance Level
- PW $1.20
- ONCT $1.30
- Average True Range (ATR)
- PW 0.09
- ONCT 0.19
- MACD
- PW -0.01
- ONCT -0.01
- Stochastic Oscillator
- PW 15.00
- ONCT 13.70
About PW Power REIT (MD)
Power REIT is a real estate investment trust (REIT) that owns real estate related to properties for Controlled Environment Agriculture, Renewable Energy and Transportation. The company is actively seeking to expand its real estate portfolio related to Controlled Environment Agriculture for the cultivation of food and cannabis. The company is focused on CEA in the form of a greenhouse which uses dramatically less energy than indoor growing, 95% less water usage than outdoor growing, and does not have any agricultural runoff of fertilizers or pesticides. To date, its greenhouse properties are operated for the cultivation of cannabis by state-licensed operators.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.